Shortages Ozempic And Wegovy Who have been in place for more than two years have been resolved, because the supplies of popular treatments for diabetes and obesity continue to improve, federal regulators said on Friday.
The drug manufacturer Novo Nordisk Can meet current and future demand in the United States, the Food and Drug Administration said. But patients can still see certain disruptions of the supply while the drugs move from the manufacturer to the distributors, then the pharmacies.
Injectable drugs have been in shortage since 2022.
In December, the FDA said that the Zepbound and Mounjaro treatment shortages from another drug manufacturer, Eli Lilly and Co., had also been resolved. Zepbound is approved to treat obesity and Mounjaro is approved for diabetes. They use the same active ingredient, shooting.
The American resolution opinion occurs almost two months after Canada, which had also undergone shortages of ozempic drugs and similar weight loss, said its supply stabilized on January 27.
Get health news on health
Receive the latest medical information and health information provided to you every Sunday.
“Ozempic and Wegovy are available across Canada, and we are not planning any future shortage at the moment,” a spokesperson for Novo Nordisk Canada said in a statement.
Ozempic, for diabetes, and Wegovy, for weight loss, use active ingredient semaglutide.
The four drugs are part of a class of GLP-1 treatments which has shown unprecedented results to help people lose weight by reducing appetite and stimulating feelings of fullness.
Sales have skyrocketed for drugs in recent years. But shortages have made access to these difficult drugs for many patients because manufacturers of drugs have run to increase production.
& Copy 2025 the Canadian press